The mitochondrial matrix is unique in that it must integrate the folding and assembly of proteins derived from the nuclear and mitochondrial genomes. In Caenorhabditis elegans, the mito chondrial unfolded protein response (UPR mt ) senses matrix protein misfolding and induces a program of nuclear gene expression, including mitochondrial chaperonins, to promote mitochondrial proteostasis 1-3 . While misfolded mitochondrialmatrixlocalized ornithine transcarbamylase induces chaperonin expression 4-6 , our understanding of mammalian UPR mt is rudimentary 7 , reflecting a lack of acute triggers for UPR mt activation. This limitation has prevented analysis of the cellular responses to matrix protein misfolding and the effects of UPR mt on mitochondrial translation to control protein folding loads. Here we combine pharmacological inhibitors of matrixlocalized HSP90/TRAP1 (ref. 8) or LON protease 9 , which promote chaperonin expression, with global transcriptional and proteomic analysis to reveal an extensive and acute response of human cells to UPR mt . This response encompasses widespread induction of nuclear genes, including matrixlocalized proteins involved in folding, preRNA processing and translation. Functional studies revealed rapid but reversible translation inhibition in mitochondria occurring concurrently with defects in preRNA processing caused by transcriptional repression and LONdependent turnover of the mitochondrial preRNA processing nuclease MRPP3 (ref. 10). This study reveals that acute mitochondrial protein folding stress activates both increased chaperone availability within the matrix and reduced matrix localized protein synthesis through translational inhibition, and provides a framework for further dissection of mammalian UPR mt .
specific inhibitor of the matrix HSP90 chaperone TRAP1 known to cause protein misfolding in this compartment 8,14 -would promote acute transcription of HSPD1 and HSPE1 as readout of UPR mt induction in HeLa cells. Acute GTPP treatment (6 h) induced UPR mt as assessed by quantitative PCR (qPCR) for HSPD1 and HSPE1 (Extended Data Fig. 1a ) with a dynamic range (approximately twofold) similar to that seen with genetic UPR mt induction in C. elegans 1 . HSPD1 and HSPE1 are among the most abundant messenger RNAs (mRNAs) in untreated cells (top 2nd percentile), explaining their limited dynamic range upon UPR mt ( Supplementary Table 1 ). GTPP treatment did not affect cell viability, mitochondrial membrane potential, ATP levels or respiratory chain architecture (Extended Data Fig. 1b-e ). Longer (24 h) incubations with GTPP result in cell death 8 . Consistent with TRAP1 being the causal target for GTPP-dependent chaperonin induction, TRAP1 RNA interference (RNAi) also induced HSPD1 by qPCR (Extended Data Fig. 1f ).
C/EBP homologous protein (CHOP), a broadly acting transcription factor, is induced via UPR er and the integrated stress response via the ATF4 transcription factor 11 . CHOP is also induced during UPR mt (refs 4, 5) and oxidative stress 15 , but the mechanisms underlying CHOP activation in UPR mt and its relationship between UPR er and integrated stress response upstream signalling remained unclear. Strikingly, we found that GTPP, but not the UPR er activator tunicamycin, respiratory chain inhibitors or mitochondrial membrane decouplers, activated HSPD1 expression ( Fig. 1a and Extended Data Fig. 2a ). GTPP also activated ATF4 and CHOP, but unlike tunicamycin, did not induce BIP, indicating that GTPP does not activate canonical UPR er (Fig. 1b, c and Extended Data Fig. 2a, b ). We also found that individual depletion of the four known EIF2A kinases involved in integrated stress response signalling (GCN2, HRI, PERK and PKR) 11 had no effect on CHOP induction by GTPP (Extended Data Fig. 2c-f ), suggesting that induction of ATF4 and CHOP by UPR mt occurs through a pathway independent of individual integrated stress response kinases 5 (Extended Data Fig. 2b ). Taken together, these data indicate that GTPP induces UPR mt through a pathway distinct from known ER and mitochondrial stress pathways (Extended Data Fig. 2b) .
To globally examine the mammalian UPR mt transcriptional response, we treated HeLa cells with GTPP for 6 h and performed RNA sequencing (RNA-seq) ( Fig. 1d , e, Extended Data Fig. 3a-b and Supplementary  Table 1 ). In parallel, we determined RNA-seq profiles upon treatment of cells with CDDO, an inhibitor of matrix protease LON (Fig. 1d ). CDDO rapidly induces mitochondrial protein misfolding 9 and induced HSPD1 expression, consistent with UPR mt induction (Extended Data Fig. 3c ). From 968 (GTPP) and 1,029 (CDDO) transcripts whose abundance changed significantly (P ≤ 0.05, log 2 ≥ ±0.6), 627 were shared between the two different treatments with 337 and 290 downregulated and upregulated transcripts, respectively, including HSPD1 and HSPE1, and CHOP (Fig. 1d-f and Extended Data Fig. 3d, e ). Importantly, changes in transcription with GTPP treatment were distinct from changes previously reported with 17-AAG 16 , a derivative of GTPP that inhibits cytoplasmic and nuclear HSP90 (Extended Data Fig. 3e ), indicating that inhibition of non-mitochondrial HSP90 is unlikely to account for the transcriptional response with GTPP. Gene ontology enrichment analysis confirmed extensive overlap in the transcriptional responses, with all gene ontology clusters representing transcripts altered with both treatments ( Fig. 1g and Supplementary Table 2 ). As expected, gene ontology terms showed enrichment for protein folding genes, consistent with UPR mt induction, but also included transfer RNA (tRNA) processing and activation. Among the nuclear genes with correlated changes in transcription, 36 encode proteins known to localize in mitochondria ( Fig. 1h and Supplementary Table 1 ). Promoter analysis of genes regulated by UPR mt induction showed enrichment of CHOP and ATF4 promoter recognition sequences, as well as two 'mitochondrial UPR Response Element' (MURE1 and MURE2) promoter elements 6 (P < 0.0001; Extended Data Fig. 4 and Supplementary Table 3 ). This analysis therefore revealed a specific nuclear response to UPR mt that is anticipated to promote homeostasis of protein folding within mitochondria.
We then applied MultiNotch proteomics 17 (Extended Data Fig. 5a ) to purified mitochondria to quantify acute changes in the mitochondrial proteome upon GTPP treatment using untreated cells or cells treated with the mitochondrial uncoupler CCCP (carbonyl cyanide-m-chlorophenyl hydrazone) as controls ( Fig. 2a and Supplementary Table 4 ) 17 . From 606 mitochondrial proteins quantified (442 with 2 or more peptides), 61 displayed significant changes in abundance 6 h after GTPP treatment compared with control or CCCP-treated cells, including HSPD1 and HSPE1, which increased as expected ( Fig. 2a, b and Extended Data Fig. 5b ). Furthermore, proteins involved in respiration, transcription, tRNA processing and protein quality control, among others, were found to be regulated (Fig. 2c ). In contrast, levels of the mitochondrial ribosome and respiratory chain complexes were not significantly altered (Extended Data Fig. 5c, d ), consistent with their long half-lives 18 . Strikingly, the abundance of the mitochondrial matrix protein MRPP3 was reduced at both the transcriptional and protein level (Fig. 1e, . MRPP3 is the catalytic subunit of the RNA-free mitochondrial RNase P complex, which also includes MRPP1 and MRPP2 (ref. 10). MRPP1 and MRPP2 mRNA and protein levels were unchanged or increased in response to GTPP or CDDO ( Fig. 2d ), suggesting a rather specific downregulation of MRPP3 in the context of RNase P.
mtDNA-derived polycistronic pre-RNA contains protein coding and ribosomal RNA elements flanked by tRNA genes. RNase P and RNase Z cleave pre-RNA 5′ and 3′ of tRNAs, respectively, with 5′ cleavage preceding 3′ cleavage 10 . Consistent with reduced MRRP3 upon UPR mt , Transcription Transport across   the membrane   Folding  HSPE1  HSPD1  TRAP1  BCL2L13  GHITM  CHCHD3  ISCU  ODF2  TMEM223  NT5DC3   Apoptosis   SPG7  MIPEP  COX5A  ATP5D  COX5B  ATP5I  NDUFA9  FOXRED1 Proteins that did not change significantly are indicated in grey. d, Histogram of protein (b) and/or mRNA ( Fig. 1 ) abundance for chaperonin and mitochondrial RNase P subunits. Two-tailed P values *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, mean of n = 3 (RNA) or n = 2 (protein) biological replicates. NS, not significant. #P = 0.06.
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we observed a 1.5-to 4.5-fold increase in non-processed mitochondrial tRNA Lys and tRNA Met 6 h after GTPP treatment ( Fig. 3a and Extended Data Fig. 6a ), comparable to effects seen upon depletion of MRPP3 by siRNA (Extended Data Fig. 6b , c). To independently examine pre-RNA processing, we analysed coverage of pre-RNA cleavage sites in tRNA Met and tRNA Lys by RNA-seq. When pre-RNA processing is defective, sequence reads from the adjacent mRNA can extend into the tRNA, indicative of reduced processing as quantified via slopes of coverage ( Fig. 3b ). Indeed, upon UPR mt , we observed increased slopes for sequence reads crossing ATP8-tRNA Lys and ND2-tRNA Met junctions ( Fig. 3c, d ). pre-RNA processing defects were absent with CCCP-dependent damage, suggesting a specific protein folding response (Extended Data Fig. 6d ). While MRPP3 mRNA and protein levels are reduced upon treatment with GTPP, CDDO resulted in reduced MRPP3 mRNA levels without reduced MRPP3 protein levels (Figs 2d and 3e ), suggesting LON-dependent MRPP3 degradation. Indeed, co-treatment with GTPP and CDDO resulted in no reduction in MRPP3 abundance ( Fig. 3e ) and, moreover, CDDO co-treatment rescued pre-RNA processing defects seen with GTPP alone (Fig. 3f ). It is currently unclear how MRPP3 is made more susceptible to degradation in response to GTPP, but we conclude that this does not occur at the level of LON abundance, as LON is not increased upon GTPP treatment (Extended Data Fig. 6e , f).
We next examined whether loss of MRPP3 and defects in pre-RNA processing during UPR mt could be overcome by its stable expression.
Previous studies have shown that alterations in the abundance of mitochondrial RNase P components can alter pre-RNA processing in unanticipated ways, making interpretation of effects of MRPP3 overexpression difficult 19 . Similarly, we found that elevated MRPP3 levels (~11-fold) altered steady-state processing efficiencies, with enhanced tRNA Met processing and tRNA Lys displaying enhanced 3′ processing and decreased 5′ processing (Extended Data Fig. 7a, b ). While MRPP3 levels were still reduced upon GTPP treatment, consistent with LON activity not being limiting, residual MRPP3 remained approximately fivefold higher than in untreated cells (Extended Data Fig. 7a ) 19 . Importantly, residual MRPP3 partly rescued tRNA Met and tRNA Lys processing (Extended Data Fig. 7c ), consistent with the notion that loss of MRPP3 during UPR mt contributes to pre-RNA processing defects.
UPR er inhibits cytosolic translation through phosphorylation of eIF2α and local degradation of mRNAs by IRE1 (ref. 11) . The alterations in genes linked with mitochondrial protein synthesis (Figs 1 and 2) together with the finding that mitochondrial pre-RNA processing is deficient during UPR mt led us to examine whether UPR mt affects translation of mRNAs derived from mtDNA (Fig. 4a ). Indeed, GTPP treatment (6 h) strongly inhibited 35 S-methionine incorporation into newly synthesized respiratory chain components in a concentrationdependent manner (Fig. 4b, c and Extended Data Fig. 8a ) without affecting cytoplasmic translation rates (Extended Data Fig. 8b ). To further validate the inhibitory effect of UPR mt on mitochondrial translation, we used stable isotope labelling by amino acids in culture (SILAC) and mass spectrometry to quantify the ratio of newly synthesized (K8-Lys) to pre-existing (K0-Lys) protein for mitochondrially encoded proteins ( Fig. 4d ). Translational inhibition was confirmed for ND5, COI, ATP6 and ATP8 ( Fig. 4d and Extended Data Figs 8c and 9a, b), with peptide coverage comparable to previous deep proteome studies in HeLa cells 20 . Translational inhibition by GTPP, as well as pre-RNA processing, was largely recovered within 4 h of GTPP wash-out ( Fig. 4e and Extended Data Fig. 10a, b ), indicating that UPR mt is rapidly reversible.
We find that acute mitochondrial folding stress promotes a multifaceted response involving (1) altered expression of nuclear genes, including mitochondrial chaperonins, to increase matrix protein folding capacity, (2) transcriptional repression and LON-dependent degradation of MRPP3 to reduce pre-RNA processing and (3) induction of rapid but reversible translational inhibition of mtDNA-encoded proteins, thereby reducing matrix folding load ( Fig. 4f ). As with pre-RNA processing (Extended Data Fig. 7b ), cells overexpressing MRPP3 display altered translation of mtDNA-encoded proteins, with ND5, COI, ND2 and COIII showing decreased translation relative to control cells (Extended Data Fig. 10c ), which complicates interpretation. However, residual MRPP3 post-GTPP treatment did not rescue bulk mitochondrial translation (Extended Data Fig. 10c ). This could reflect sub-threshold levels of tRNA processing despite partial rescue (Extended Data Fig. 7) or redundancy in the UPR mt pathway, thereby affecting other steps in the translation pathway ( Fig. 4f) , as is the case with UPR er (ref. 11) . Alternatively, because MRPP1-dependent tRNA methylation critical for tRNA maturation requires assembly with MRPP3 (ref. 21), MRPP3 overexpression may uncouple pre-RNA processing from tRNA methylation, resulting in translational defects despite the presence of MRPP3. While the TFB1M methyltransferase responsible for mitochondrial 12S rRNA methylation is reduced transcriptionally (Fig. 1h ), its protein abundance is unchanged at 6 h post-GTPP (Extended Data Fig. 10d ), indicating that defects in rRNA methylation do not underlie translational inhibition. Thus, further studies are required to understand the regulation of mitochondrial translation with and without mitochondrial stress. In keeping with the transient nature of stress responses 13 , our work has focused on acute effects of UPR mt . Components linking mitochondrial protein misfolding to the nucleus remain to be identified, as ATFS-1 orthologues are lacking in mammals. Interestingly, the stress-inducible protein ATF3 to ATFS-1, and which can function with CHOP, is also induced 1.5-to 4-fold by UPR mt ( Supplementary Table 1 ), suggesting a possible role in UPR mt signalling. Prolonged UPR mt and concomitant translational inhibition probably leads to confounding effects that would be detrimental to mitochondrial health, consistent with the application of GTPP to cancer therapeutics 14 . The transcriptional and proteomic data reported here provide a framework for the further elucidation of circuits that contribute to protein homeostasis within mitochondria, and for the development of approaches that can manipulate the response of cells to mitochondrial folding stress, as might occur in pathological conditions including cancer and neurodegenerative diseases.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Cell. Biol. 24, 1365 -1377 (2004 .
Supplementary Information is available in the online version of the paper. Fig. 9c ); *signal-to-noise ratios too low for accurate assessment. e, Reversibility of translation inhibition was measured using a GTPP pulse-chase assay wherein GTPP was washed out for 1-4 h (top). Translation rates are average values ± s.d. across the 13 mitochondrially encoded proteins, twotailed P values *P ≤ 0.05, ***P ≤ 0.001 and derived from SDS-PAGE of translation products (lower left) as described in a. f, Model of the cellular responses to UPR mt induction. See text for details.
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MethOdS Chemicals and antibodies. LysC (VWR catalogue number 100369-822), CDDO (Cayman Chemicals catalogue number 81035), emetine (Sigma catalogue number E2375), CCCP (Sigma catalogue number C2759), rotenone (Sigma catalogue number R8875), paraquat (Sigma catalogue number 36541), TTFA (Sigma catalogue number T27006), 3-Nitropropionic acid (Sigma catalogue number N5636), antimycin A (Sigma catalogue number A8674), myxothiazole (Sigma catalogue number T5580), potassium cyanide (Sigma catalogue number 60178), valinomycin (Sigma catalogue number V0627) and K8 lysine (Cambridge Isotopes). An original aliquot of GTPP was a gift from D. C. Altieri; a second aliquot was custom synthesized by Shanghai ChemPartner Co. Antibodies used were anti-MRPP3 (LSBio catalogue number LS-C332515, western blot: 1:500), anti-TOM20 (Santa Cruz catalogue number sc-11415, western blot: 1:500), anti-LON (Sigma catalogue number HPA002192, western blot 1:500), anti-ACTIN (Santa Cruz catalogue number sc69879, western blot 1:500), anti-TFB1M (Abcam, catalogue number 69871, western blot 1:400), anti-NDUFA9 (Abcam catalogue number ab14713, blue native 1:1,000), anti-SDHA (Abcam catalogue number ab14715, blue native 1:1,000) and anti-UQCRC2 (Abcam catalogue number ab14745, blue native 1:1,000). Cell culture and assays for cytotoxicity, mitochondrial membrane potential and cellular ATP levels. HeLa cells were purchased from the American Type Culture Collection (ATCC) and not further authenticated. They were confirmed to be mycoplasma negative, and grown in RPMI medium supplemented with 1× glutamax (Invitrogen catalogue number 61870-127) and 10% fetal bovine serum. For all experiments, cells were treated with DMSO and 10 μM GTPP (or concentration as indicated) and/or 2.5 μM CDDO for 6 h. For CCK8 cytotoxicity assays, cells were plated in clear bottom 96-well plates, processed according to the manufacturer's instructions (CCK8 Dojindo CK04-05) and quantified on a VersaMax microplate reader (Molecular Devices). For mitochondrial membrane potential determination, cells were treated with JC-1 (Life Technologies catalogue number T3168) according to the manufacturer's instructions. Cells were harvested and analysed by fluorescence-activated cell sorting on a BD FACSCalibur. To assess cellular ATP levels, cells were plated on 96-well clear-bottom plates and treated with DMSO, GTPP or 100 μM antimycin A. ATP levels were measured with the Mitochondrial ToxGlo assay (Promega G8000) and analysed on a Molecular Devices SpectraMax M5 multi-mode plate reader. Quantitative PCR and RNA sequencing. Total RNA was harvested using NucleoSpin RNA or NucleoSpin miRNA for analysis of pre-RNA processing (Macherey-Nagel catalogue numbers 740955 and 740971). RNA was quantified and equal amounts were reverse transcribed into complementary DNA (cDNA) using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems catalogue number 4368814). Quantitative PCR was performed using TaqMan Fast universal PCR Master Mix (Applied Biosystems catalogue number 4366072) or Fast SYBR Green Master Mix (Life Technologies catalogue number 4385612) using an Applied Biosystems 7500 Fast Real-time PCR machine with the following primers: tRNA Met forward: AGTAAGGTCAGCTAAATAAG, tRNA Met 5′ upstream forward: GAATCGAACCCATCCCTGAG, tRNA Met reverse: TAGTACGGGAAGGGTATAACC, tRNA Met downstream reverse: GTGTGCCTGCAAAGATGGTAG, tRNA Lys forward: CACTGTAAAGCTAA CTTAGC, tRNA Lys 5′ upstream forward: GAAATAGGGCCCGTATTTACC, tRNA Lys reverse: TCACTGTAAAGAGGTGTTGG, tRNA Lys 3′ downstream reverse: GATGAGGAATAGTGTAAGGAG, GAPDH forward: ATGCCTCCTGC ACCACCAAC, GAPDH reverse: GGGGCCATCCACAGTCTTCT, ND4 forward: CTTCGAAACCACACTTATCC, ND4 reverse: GTATGCAATGAGCGATTT TAGG, or Life Technologies TaqMan probes for GAPDH (Hs02758991_g1), HSPD1 (Hs03044918_g1), HSPE1 (Hs01654720_g1), MRPP3 (Hs00206448_m1), TRAP1 (Hs00212474_m1), DDIT3 (Hs00358796_g1), ATF4 (Hs00909569_g1) and BIP (Hs00607129_gH). For analysis of pre-RNA processing, data were normalized to tRNA levels obtained from using internal forward and reverse tRNA primers. For analysis of integrated stress response activation, cells were treated with 10 μM GTPP, 10 μg ml −1 tunicamycin, 5 μM rotenone, 0.5 mM paraquat, 0.5 mM TTFA, 10 mM 3NP, 100 μM antimycin A, 3 μM myxothiazol, 1 mM KCN, 10 μM CCCP or 1 μM valinomycin for 6 h before purification and analysis of RNA levels by quantitative PCR.
For RNA sequencing, total RNA samples were submitted to the Harvard Bauer Core Facility for processing (ribosomal depletion with RiboZero), directional RNA-seq library preparation and 12 cycle amplification using LongAmp (New England BioLabs) and indexed primers (Integrated DNA Technologies), quality control and sequencing in one flow cell on a 75 bp paired-end NextSeq for transcriptome analysis or one lane on a 100 bp paired-end HiSeq to monitor mitochondrial RNA processing. For transcriptome analysis, reads were examined by FastQC and analysed by the tophat2 version 1.2 analysis pipeline by Harvard Medical School Research Computing against hg19, consisting of analysis by tophat, cufflinks, and cuffmerge. For analysis of mitochondrial pre-RNA processing, reads were examined by FastQC, trimmed with cutadapt (for PHRED scores below five) and aligned to hg19 (augmented with transcript information from GRCh37.75) by STAR. Alignments were checked by FastQC and RNA-SeQC, and read counts of known genes detected by featureCounts.
To analyse the RNA-seq data set for pre-RNA processing, coverage data across a tRNA/mRNA region was normalized for reads within the protein-coding gene region across all six experimental conditions at every cut site. Slopes of the first ten nucleotides within the tRNA genes adjacent to the cut site were determined in Microsoft Excel (presented slopes had correlation values of R ≥ 0.9) and calculated as an average of the mean with two-tailed P values. Gene ontology enrichment analysis. Sets of genes of interest were uploaded and searched with the DAVID online tool (http://david.abcc.ncifcrf.gov/home.jsp) for enriched biological processes (GOTERM_BP_FAT). Functional annotation charts were saved and visualized with the enrichment map app (version 2.0.1) 23 in cytoscape (version 3.2.1, P ≤ 0.001). Clusters were annotated according to their general functional with their overlapping biological process. Promoter analysis. Three thousand bases upstream of the transcription start site of the transcripts encoding mitochondrial proteins and regulated by UPR mt were extracted from ensemble. These promoter sequences were analysed by FIMO (Find Individual Motif Occurrences, version 4.11.1) 24 . Motifs were provided as indicated and scanned on a provided DNA database with the listed promoter sequences. P values were set at 0.0001 and defined as the probability of random sequences of identical length achieving a similar or better score as the sequence provided. RNAi experiments. Cells were grown on 12-well plates and RNAi was transfected with Lipofectamine 3000 (Life Technologies) according to the manufacturer's instructions. RNAi used was MRPP3 (Ambion, AM16708, ID 21858), and TRAP1 (DF/HCC DNA Resource Core IDs: HsSH00112394, HsSH00112407), EIF2AK1 (Dharmacon LQ-005007-00-0002), EIF2AK2 (Dharmacon LQ-003527-00-0002), EIF2AK3 (Dharmacon LQ-004883-00-0002) and EIF2AK4 (Dharmacon LQ-005314-00-0002). Cell line generation. Human cDNA for MRPP3 was purchased from Sino Biological (HG14131-G) and transferred into a pHAGE lentiviral vector. Virus particles were produced in HEK293T cells after transfection with the lentivial vector and helper vectors (VSVG, Tat1b, Mgpm2, CMV-Rev) and used to infect HeLa cells. Cells were selected in 1 μg ml −1 puromycin. Mass spectrometry. For quantitative analysis of the mitochondrial proteome, HeLa cells were treated with 10 μM GTPP, CCCP, or DMSO for 6 h. Mitochondria were purified as previously described using Basic Protocol 1 (ref. 25). Briefly, cells were scraped into cold PBS, collected by centrifugation, resuspended in lysis buffer and sonicated. Crude mitochondria were acquired by differential centrifugation and purified mitochondria obtained by separation on a sucrose cushion. Similar amounts of mitochondria were obtained under the different treatments. Mitochondrial pellets were resuspended in lysis buffer (6 M GdnHCl, 75 mM NaCl, 50 mM Tris, pH 8.5, 1 mM PMSF, 1× OPT) and sonicated. Samples were reduced, alkylated with iodoacetamide and proteins were precipitated using chloroform/ methanol. Protein pellets were resuspended in 8 M urea in 50 mM Tris, pH 8.8 and subsequently diluted with 50 mM Tris, pH 8.8 to a urea concentration of 2 M. Proteins were digested with LysC overnight at 37 °C. Digestion reactions were stopped by addition of formic acid, dried and purified by C18 stage tip. Samples were taken up in 0.2 M HEPES, pH 8.5 buffer, quantified by micro BCA (Thermo Scientific catalogue number 23235) and labelled with TMT 6-plex reagents (Thermo Scientific) for 1 h at room temperature. Reactions were stopped by addition of 5% hydroxylamine for 15 min followed by addition of formic acid. Equal amounts of peptide samples were combined to a total of 10 μg and purified on a C18 stage tip. Dried peptides were resuspended in 5% acetronitrile/5% formic acid and analysed on an Orbitrap Fusion (Thermo Scientific) running a 2 h gradient from 6% to 30% acetonitrile using a multi-notch MS3-based method 17 selecting ten MS2 fragment ions for analysis by MS3 (Orbitrap, AGC 5 × 10 4 , 60,000 resolution, maximum injection time 150 ms). Peptides were identified and quantified by a SEQUEST-based in-house tool (developed by the S. P. Gygi laboratory) using SEQUEST with a human UniProt database (as of 14 January 2014), and submitted to linear discriminant analysis to score peptides and proteins with protein and peptide FDR values of 2% (ref. 26) . Proteins were collapsed to a protein-level FDR of 2%. Searches were run for LysC with a maximum of two missed cleavage sites and with carbamidomethylation of cysteine residues and TMT tags on lysine residues and N termini as static modifications, and methionine oxidation as variable modification. TMT-based quantitation was performed by TMT-reporter ion analysis for all identified proteins. MS3 spectra with a summed signal-to-noise ratio of <100 were excluded and the TMT channels normalized across all TMT channels (with resulting normalization factors between 1 and 1.252). For final analysis of quantified proteins, values were transferred and analysed in Microsoft Excel and the following cut-offs were applied: minimum number of two quantified Extended Data Figure 2 | UPR mt signals distinctly from the integrated stress response. a, Table with summarized results of data shown in Fig. 1a -c. Induced genes are labelled green and compounds are clustered into their molecular function. GTPP induces UPR mt and tunicamycin ER UPR. All other compounds affect mitochondrial respiration and/or the mitochondrial membrane potential. b, Schematic showing how different stresses signal through the integrated stress response pathway based on the results shown in b and Fig. 1a -c. c, Quantitative PCR to assess the mRNA knockdown of the four EIF2A kinases by siRNA smart pools in biological duplicate; repl., replicate d, Quantitative PCR monitoring CHOP mRNA levels in untreated or GTPP-treated cells with or without knockdown of the EIF2A kinases as in c. e, Quantitative PCR to monitor PERK mRNA levels upon PERK knockdown with individual siRNAs in biological duplicate. f, Quantitative PCR monitoring CHOP mRNA levels in GTPPtreated cells with or without knockdown of PERK by individual siRNAs in biological duplicate.
Extended Data Figure 3 | Global analysis of transcriptional responses to UPR mt induction. a, Heatmap of measured transcript abundances of cells treated with DMSO, 10 μM GTPP or 2.5 μM CDDO for 6 h (n = 3 biological replicates). Values not passing the cuffdiff threshold of FPKM abundance and read number were excluded (white). b, Correlation of replicates for DMSO-, GTPP-and CDDO-treated samples with R values depicting correlation value; log 10 -transformed FPKM values (≥0) are plotted. c, Quantitative PCR monitoring induction of mt UPR by measuring chaperonin mRNA levels upon treatment with DMSO or CDDO. Shown are means of levels relative to DMSO-treated ± s.d. (n = 3 biological replicates). d, Correlation between the abundance of transcripts significantly altered in GTPP-versus CDDO-treated cells (Fig. 1c , combined panel). e, Table representing changed transcripts upon GTPP or CDDO treatment (Fig. 1c ) compared with the number of transcripts changed upon 17AAG previously reported 16 .
